In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.
No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.
What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.
Link to the report home page, summary, and PDFs of the full report.
Researchers led by Stephanie Vos and Pieter Jelle Visser at Maastricht University in the Netherlands and Anne Fagan and others at Washington University in St. Louis, Missouri, analyzed data from 311 cognitively normal elderly people seen at St. Louis’s Knight Alzheimer’s Disease Research Center.
A team of scientists, including Paul Aisen, MD, professor of neuroscience and director of the Alzheimer’s Disease Cooperative Study, issued a sort of post-mortem on semagacestat, a small-molecule gamma-secretase inhibitor that drug developer Eli Lilly hoped would prove to be an effective treatment for Alzheimer’s disease (AD).
We are thrilled to begin the New Year with over 50,000 participants in Brain Health Registry! We are grateful for your help in achieving this significant milestone, and cannot thank you enough for your efforts to help scientists better understand brain disease.
Dr Sadowski talks about the potential of the EXERT Study to help identify the right dose of exercise to offset memory loss for people at risk for Alzheimer’s disease
One of the longest and most anticipated Alzheimer drug studies in history is about to begin, and Dr. Reisa Sperling is wondering if people will come. It’s called the A4 study, and Sperling is the project leader.
Howard Feldman of University of British Columbia is known for seminal research in dementias; UC launches new $4 million Alzheimer’s disease initiative.
People spend about a third of their lives asleep. When we get too little shut-eye, it takes a toll on attention, learning and memory, not to mention our physical health. Virtually all animals with complex brains seem to have this same need for sleep. But exactly what is it about sleep that’s so essential?
A need exists for a simple, less-invasive test to diagnose Alzheimer’s disease and similar neurodegenerative conditions in living people, perhaps even before memory loss becomes obvious.
Epidemiologic evidences support that habitual caffeine intake prevents memory decline during aging and reduces the risk to develop Alzheimer’s disease. So far, experimental studies addressed the impact of caffeine in models mimicking the amyloid pathology of AD. However, in vivo effects of caffeine in a model of AD-like tauopathy remain unknown.
Levels of neurogranin, a cerebrospinal fluid (CSF) biomarker for synaptic loss, were elevated in patients with Alzheimer’s disease (AD) compared with cognitively normal individuals. Neurogranin levels also predicted progression from mild cognitive impairment (MCI) to AD dementia, researchers reported here on Monday at the Alzheimer’s Association International Conference (AAIC).
Identifying the genes involved in Alzheimer’s disease and related dementias is of course no easy task. From among the thousands of gene candidates in the human genome, we need to determine which are involved in onset and progression, and which increase risk or offer protection.
Nancy Reagan, the influential and stylish wife of the 40th president of the United States who unabashedly put Ronald Reagan at the center of her life but became a political figure in her own right, died on Sunday at her home in Los Angeles. She was 94.
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications.
As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer’s disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers.